CNSX:BUZZ

VanEck Vectors Social Sentiment ETF Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive BUZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for VanEck Vectors Social Sentiment ETF and its competitors with MarketBeat's FREE daily newsletter.


About VanEck Vectors Social Sentiment ETF

Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates in the psychedelic smartshop market. In addition, the company engages in the adult use psychedelic retail business; and researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of Cepharanthine. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











VanEck Vectors Social Sentiment ETF (CNSX:BUZZ) Frequently Asked Questions

What stocks does MarketBeat like better than VanEck Vectors Social Sentiment ETF?

Wall Street analysts have given VanEck Vectors Social Sentiment ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VanEck Vectors Social Sentiment ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are VanEck Vectors Social Sentiment ETF's key executives?

VanEck Vectors Social Sentiment ETF's management team includes the following people:
  • Mr. Daniel Cohen, Chairman & CEO
  • Mr. Keith Li, Chief Financial Officer (Age 40, Pay $91k)
  • Dr. Paul Van Slyke, Chief Scientific Officer
  • Harry Resin, Pres of Super Smart

Who are some of VanEck Vectors Social Sentiment ETF's key competitors?

What other stocks do shareholders of VanEck Vectors Social Sentiment ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Social Sentiment ETF investors own include Aphria (APHA), Annovis Bio (ANVS), Amex Exploration (AMX), Amyris (AMRS), (AMPE), Alpha Lithium (ALLIF), Aleafia Health (ALEAF), Aldeyra Therapeutics (ALDX), Agraflora Organics International (AGRA) and Acreage (ACRGF).

What is VanEck Vectors Social Sentiment ETF's stock symbol?

VanEck Vectors Social Sentiment ETF trades on the CNSX under the ticker symbol "BUZZ."

How do I buy shares of VanEck Vectors Social Sentiment ETF?

Shares of BUZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VanEck Vectors Social Sentiment ETF's official website?

The official website for VanEck Vectors Social Sentiment ETF is www.pharmadrug.co.

How can I contact VanEck Vectors Social Sentiment ETF?

The company can be reached via phone at 647 202 1824.


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.